Ranitidine may pass into breast milk and cause side effects in a child who is breastfed. You may need to ask your doctor to help you weigh the benefits of breastfeeding versus taking this drug. For seniors: The kidneys of older adults may not work as well as they used to. In rare cases, this drug may cause confusion, agitation, depression, and hallucinations.
These problems happen most often in seniors who are very ill. For children: Ranitidine has not been confirmed as safe and effective in children younger than 1 month for any condition. Ranitidine has not been confirmed as safe and effective in people younger than 18 years for conditions where the stomach makes too much acid.
These conditions include Zollinger-Ellison syndrome. Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.
The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Find ways to relieve or prevent heartburn after eating. Gastroesophageal reflux disease GERD is a chronic condition that affects nearly 20 percent of American adults. Learn the complications from GERD…. Do you prefer tea to coffee? If you have acid reflux, a cup of chamomile tea may have additional health benefits. Stomach ulcers are open sores in the lining of the stomach.
They are often extremely painful. Read on to learn about easy stomach ulcer home remedies…. GERD gastroesophageal reflux disease is a chronic form of heartburn. Learn about symptoms and treatment. Numerous over-the-counter medications can help treat GERD, or heartburn.
Learn more about your options for treating GERD and when you should see a…. H2 receptor blockers can be used to treat conditions that cause excess stomach acid. Learn about the side effects of these medications.
Zantac is an over-the-counter OTC drug that can ease heartburn. Excess stomach acid and the damage it can cause can happen in babies. Learn if Zantac may be an option for your baby. Do you deal with heartburn more than twice a week? You could be dealing with GERD.
Learn what causes it, and what treatment options are available. Health Conditions Discover Plan Connect. Ranitidine, Oral Tablet. Written by University of Illinois on May 21, Highlights for ranitidine. What is ranitidine? Ranitidine side effects. Ranitidine may interact with other medications. How to take ranitidine. Take as directed. Important considerations for taking this drug. Are there any alternatives? Ranitidine warnings.
Natural and Home Remedies for Ulcers. Read this next. Rare reports have suggested that ranitidine may precipitate acute porphyric attacks in patients with acute porphyria.
It is recommended that ranitidine be avoided in these patients. Tobacco smoking appears to contribute to an increased risk of developing peptic ulcer disease PUD and may also impair ulcer healing or increase the risk of ulcer recurrence.
Encourage patients taking ranitidine to discontinue tobacco smoking if diagnosed with PUD. Rarely, bradycardia has been reported with the rapid intravenous administration of ranitidine injection.
In most cases, bradycardia was observed in patients with factors predisposing to cardiac rhythm disturbances. When administering ranitidine injection, the recommended rates of administration should not be exceeded; caution is warranted in elderly patients as well as patients with underlining cardiac disease.
No special precautions for ranitidine use have been advised for geriatric patients vs. Critically ill, elderly patients in some uncontrolled studies have been more likely to exhibit central nervous system CNS reactions to the H2-receptor antagonists.
Elderly patients may also be more likely to experience a reduction in heart rate during the rapid administration of ranitidine injection. If the H2-antagonist is used for longer than 12 weeks, clinical rationale and documentation should support an underlying chronic disease e.
Dosing should be based on renal function. Adverse consequences of medication therapy include new or worsening headaches, confusion, nausea, vomiting, flatulence, dysphagia, abdominal pain, diarrhea, or other GI symptoms. Also, ranitidine has anticholinergic properties which may be problematic in the elderly.
Daily treatment with gastric acid-suppressing medication such as nizatidine over a long period of time e. One large case-controlled study compared patients with and without an incident diagnosis ofvitamin B12 deficiency. In addition, a dose-dependant relationship was evident, as larger daily pill counts were more strongly associated with vitamin B12 deficiency.
The possibility of cyanocobalamin deficiency should, therefore, be considered if clinical symptoms are observed. Acalabrutinib: Moderate Separate the administration of acalabrutinib and H2-blockers if these agents are used together; administer acalabrutinib 2 hours before the H2-blocker. Acalabrutinib solubility decreases with increasing pH values; therefore, coadministration may result in decreased acalabrutinib exposure and effectiveness. Acetohexamide: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas.
Patients receiving sulfonylureas should be observed for evidence of altered glycemic response when ranitidine is instituted or discontinued. The mechanism of this interaction may involve either increasing the absorption or decreasing the clearance of the sulfonylurea.
Asymptomatic hypoglycemia has been observed as a result of this interaction. It is unclear at this time if famotidine or nizatidine interact with oral sulfonylureas. Alendronate: Moderate Although the clinical significance has not been determined, the bioavailability of oral alendronate is doubled by concomitant administration of intravenous ranitidine. Investigations have not been undertaken to determine if other H2-antagonists have a similar effect on bioavailability.
Patients should be closely monitored when H2-blockers are coadministered as they may affect the bioavailability of alendronate, possibly leading to a higher likelihood of developing adverse effects while taking alendronate.
Alendronate; Cholecalciferol: Moderate Although the clinical significance has not been determined, the bioavailability of oral alendronate is doubled by concomitant administration of intravenous ranitidine. Alogliptin; Pioglitazone: Minor Concentrations of pioglitazone may be decreased with concomitant use of ranitidine. The effect of capistration on the systemic exposure of pioglitazone was determined in a drug-drug interaction study.
Close monitoring of blood glucose is recommended; dosage adjustments in pioglitazone may be needed. Amphetamine; Dextroamphetamine Salts: Moderate The use of H2-blockers with amphetamine therapy may change the onset of action of amphetamine or dextroamphetamine due to the increase in gastric pH.
The time to maximum concentration Tmax of these amphetamines is decreased compared to when administered alone, thus increasing stimulant concentrations, which may be of particular significance with extended-release dosage forms.
Monitor clinical response and adjust if needed. Atazanavir: Major Coadministration of H2-blockers with atazanavir reduces serum atazanavir concentrations; however, H2-blockers can be used under specific administration restrictions.
Significant reductions in atazanavir serum concentrations may lead to therapeutic failure and the development of HIV resistance. Closely monitor patients for antiretroviral therapeutic failure and resistance development during treatment with an H2- blocker. Atazanavir; Cobicistat: Major Coadministration of H2-blockers with atazanavir reduces serum atazanavir concentrations; however, H2-blockers can be used under specific administration restrictions.
Atracurium: Moderate Ranitidine may cause resistance to atracurium-induced neuromuscular blockade, due to pharmacodynamic alterations at the acetylcholine receptor. In vitro studies demonstrate that therapeutic serum concentrations of ranitidine inhibit acetylcholinesterase, thus increasing the amount of acetylcholine available to compete at the neuromuscular junction and reverse the neuromuscular blockade.
The inhibition of acetylcholinesterase is likely dose-related. Resistance to nondepolarizing neuromuscular blockers was reported occasionally with intravenous ranitidine dosages that were slightly higher than those given clinically, but not frequently with oral therapy. Bisacodyl: Minor The concomitant use of bisacodyl tablets with H2-blockers can cause the enteric coating of the bisacody tablet to dissolve prematurely, leading to possible gastric irritation or dyspepsia.
Avoid H2-blockers within 1 hour before or after the bisacodyl dosage. Bismuth Subsalicylate: Minor H2-blockers may increase the systemic absorption of bismuth from bismuth-containing compounds like bismuth subsalicylate.
Bismuth Subsalicylate; Metronidazole; Tetracycline: Minor H2-blockers may increase the systemic absorption of bismuth from bismuth-containing compounds like bismuth subsalicylate. Bosutinib: Moderate Bosutinib displays pH-dependent aqueous solubility; therefore, concomitant use of bosutinib and H2-blockers may result in decreased plasma exposure of bosutinib. Separate the administration of bosutinib and H2-blockers by more than 2 hours. Budesonide: Moderate Monitor for altered response to budesonide in patients receiving H2-blockers with enteric-coated or extended-release formulations of oral budesonide.
Likewise, the dissolution of the coating of extended-release budesonide tablets Uceris is pH dependent. Concomitant use of oral budesonide and antacids, milk, or other drugs that increase gastric pH levels can cause these products to dissolve prematurely, possibly affecting release properties and absorption of the drug in the duodenum.
Budesonide; Formoterol: Moderate Monitor for altered response to budesonide in patients receiving H2-blockers with enteric-coated or extended-release formulations of oral budesonide.
Budesonide; Glycopyrrolate; Formoterol: Moderate Monitor for altered response to budesonide in patients receiving H2-blockers with enteric-coated or extended-release formulations of oral budesonide. Cabotegravir; Rilpivirine: Moderate Coadministration with ranitidine may significantly decrease rilpivirine plasma concentrations, potentially resulting in treatment failure. To decrease the risk of virologic failure, avoid use of ranitidine for at least 12 hours before and at least 4 hours after administering rilpivirine.
Calcium Carbonate; Risedronate: Major Use of H2-blockers with delayed-release risedronate tablets Atelvia is not recommended. Co-administration of drugs that raise stomach pH increases risedronate bioavailability due to faster release of the drug from the enteric coated tablet.
This interaction does not apply to risedronate immediate-release tablets. Cefditoren: Moderate Cefditoren pivoxil absorption may be decreased by H2-blockers. Coadministration is not recommended. The clinical significance of this interaction is not known. Cefpodoxime: Moderate H2-blockers should be avoided during treatment with cefpodoxime.
Coadministration could result in antibiotic failure. H2-blockers increase gastric pH. Cefpodoxime proxetil requires low gastric pH for dissolution. Ceftibuten: Minor H2-blockers can affect the pharmacokinetics of some orally-administered cephalosporins. The oral bioavailability of ceftibuten was reported to be increased by the administration of mg of ranitidine PO every 12 hours for 3 days, but this interaction is of unknown clinical relevance.
Cefuroxime: Major Avoid the concomitant use of H2-blockers and cefuroxime. Drugs that reduce gastric acidity, such as H2-blockers, can interfere with the oral absorption of cefuroxime axetil and may result in reduced antibiotic efficacy. Chlorpropamide: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas. Cisatracurium: Moderate Ranitidine may cause resistance to cisatracurium-induced neuromuscular blockade, due to pharmacodynamic alterations at the acetylcholine receptor.
Cyclosporine: Minor Although data are conflicting, cautious use of ranitidine and cyclosporine is warranted; cyclosporine can cause nephrotoxicity, and ranitidine is substantially excreted by the kidney. The risk of toxic reactions to ranitidine may be greater in patients with impaired renal function; ranitidine dose reduction is needed for renal impairment. Cysteamine: Major Monitor white blood cell WBC cystine concentration closely when administering delayed-release cysteamine Procysbi with H2-blockers.
Drugs that increase the gastric pH may cause the premature release of cysteamine from delayed-release capsules, leading to an increase in WBC cystine concentration. Dacomitinib: Major Administer dacomitinib at least 6 hours before or 10 hours after taking ranitidine due to the risk of decreased plasma concentrations of dacomitinib which may impact efficacy.
Darunavir: Minor No change in darunavir concentrations was observed when coadministered with ranitidine. Darunavir can be coadministered with H2-blockers without any dosage adjustments. Darunavir; Cobicistat: Minor No change in darunavir concentrations was observed when coadministered with ranitidine.
Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: Minor No change in darunavir concentrations was observed when coadministered with ranitidine.
Dasatinib: Major Do not administer H2-blockers with dasatinib due to the potential for decreased dasatinib exposure and reduced efficacy. Consider using an antacid if acid suppression therapy is needed. Administer the antacid at least 2 hours prior to or 2 hours after the dose of dasatinib. Delavirdine: Major Coadministration of delavirdine with H2-blockers results in decreased absorption of delavirdine.
Administration of delavirdine and H2-blockers should be separated by at least 1 hour. Chronic use of H2-blockers with delavirdine is not recommended. Diphenhydramine; Naproxen: Moderate The enteric-coated, delayed-release naproxen tablets are designed to dissolve at a pH of 6 or greater. Concomitant use of this particular naproxen product with H--blockers is not recommended due to the gastric pH alteration. Dolutegravir; Rilpivirine: Moderate Coadministration with ranitidine may significantly decrease rilpivirine plasma concentrations, potentially resulting in treatment failure.
Donepezil; Memantine: Minor Memantine is excreted in part by renal tubular secretion. Competition of memantine for excretion with other drugs that are also eliminated by tubular secretion, such as ranitidine, could result in elevated serum concentrations of one or both drugs. Emtricitabine; Rilpivirine; Tenofovir alafenamide: Moderate Coadministration with ranitidine may significantly decrease rilpivirine plasma concentrations, potentially resulting in treatment failure.
Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: Moderate Coadministration with ranitidine may significantly decrease rilpivirine plasma concentrations, potentially resulting in treatment failure. Entecavir: Moderate Both entecavir and ranitidine are secreted by active tubular secretion. In theory, coadministration of entecavir with ranitidine may increase the serum concentrations of either drug due to competition for the drug elimination pathway.
The manufacturer of entecavir recommends monitoring for adverse effects when these drugs are coadministered. Erlotinib: Major If concomitant use of erlotinib with ranitidine is necessary, erlotinib must be taken 10 hours after the last dose of ranitidine and at least 2 hours before the next dose. Erlotinib displays pH-dependent solubility with decreased solubility at a higher pH; the increased gastric pH resulting from ranitidine therapy may reduce the bioavailability of erlotinib.
Increasing the dose of erlotinib without modifying the administration schedule is unlikely to compensate for loss of exposure. Ethanol: Minor Some studies have suggested that H2-receptor antagonists inhibit gastric alcohol dehydrogenase and thus decrease the first pass metabolism of alcohol, and some studies have suggested an interaction may not always occur.
A meta-analysis evaluating the effects of H2-blockers on blood alcohol concentrations reported that only cimetidine and ranitidine, but not other H2-blockers, caused small elevations in serum alcohol levels. However, it was reported that larger studies were less likely to show an effect and that these elevations were not likely to be clinically relevant.
Flibanserin: Moderate The concomitant use of flibanserin and multiple weak CYP3A4 inhibitors, including ranitidine, may increase flibanserin concentrations, which may increase the risk of flibanserin-induced adverse reactions. Therefore, patients should be monitored for hypotension, syncope, somnolence, or other adverse reactions, and the risks of combination therapy with multiple weak CYP3A4 inhibitors and flibanserin should be discussed with the patient.
Fosamprenavir: Moderate The coadministration of fosamprenavir with H2-blockers decreases amprenavir plasma concentrations. Use these drugs together with caution as amprenavir plasma concentrations may be decreased, which could lead to loss of virologic response and possible viral resistance to fosamprenavir.
Gefitinib: Major Avoid coadministration of ranitidine with gefitinib if possible due to decreased exposure to gefitinib, which may lead to reduced efficacy. If concomitant use is unavoidable, take gefitinib 6 hours after the last dose or 6 hours before the next dose of ranitidine. Gefitinib exposure is affected by gastric pH. Glimepiride: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas. Glimepiride; Rosiglitazone: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas.
Glipizide: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas. Glipizide; Metformin: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas. Glyburide: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas.
Glyburide; Metformin: Moderate Ranitidine has been shown to affect the pharmacokinetics of some oral sulfonylureas. Infigratinib: Moderate Separate the administration of infigratinib and H2-receptor antagonists if concomitant use is necessary.
Coadministration may decrease infigratinib exposure resulting in decreased efficacy. Administer infigratinib two hours before or ten hours after an H2-receptor antagonist. Iron: Minor The bioavailability of oral iron salts is influenced by gastric pH, and the concomitant administration of H2-blockers can decrease iron absorption.
The non-heme ferric form of iron needs an acidic intragastric pH to be reduced to ferrous and to be absorbed. Iron salts and polysaccharide-iron complex provide non-heme iron. H2-blockers have long-lasting effects on the secretion of gastric acid and thus, increase the pH of the stomach. The increase in intragastric pH can interfere with the absorption of iron salts. Itraconazole: Moderate When administering H2-blockers with the mg itraconazole capsule and mg itraconazole tablet formulations, systemic exposure to itraconazole is decreased.
Conversely, exposure to itraconazole is increased when H2-blockers are administered with the 65 mg itraconazole capsule. Administer H2-blockers at least 2 hours before or 2 hours after the mg capsule or mg tablet. Do not stop taking this medication without consulting your doctor. Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take this medication if their doctor has not prescribed it.
Zantac 75 mg Each pink, five-sided, biconvex, film-coated tablet, with "Z" engraved on one side and "75" on the other, contains 84 mg of ranitidine HCl equivalent to 75 mg of ranitidine anhydrous free base. Nonmedicinal ingredients: tablet: magnesium stearate and microcrystalline cellulose; film-coating: hypromellose, iron oxide, titanium dioxide, and triacetin.
Gluten-, sodium-, and sucrose-free. Zantac Maximum Strength Non-Prescription Each dark pink, five-sided, biconvex, film-coated tablet with "Z" engraved on one side and "" on the other, contains mg of ranitidine HCl equivalent to mg of ranitidine anhydrous free base. Also contains synthetic red iron oxide. The recommended adult dose of ranitidine ranges from mg daily to mg twice daily or mg once daily depending on the condition being treated.
Ranitidine may be taken with or without food. When used over-the-counter to treat acid indigestion, heartburn, or sour or upset stomach, the usual dose for adults and children 16 years of age or older is 75 mg to mg taken when symptoms appear. If symptoms persist for more than 1 hour or return after 1 hour, you may take a second dose of the same strength. To prevent symptoms brought on by consuming food or beverages, take the dose 30 to 60 minutes before eating food or drinking beverages that are expected to cause symptoms.
The maximum dose is mg every 24 hours. Do not take it in this manner for more than 2 weeks without seeking medical advice.
Injection: The injectable form of ranitidine may be used in hospitals under specific circumstances when the patient is not able to swallow tablets. The usual dose of ranitidine injection is 50 mg every 6 to 8 hours given intravenously into a vein or intramuscularly into a muscle. If you are using the oral liquid form of ranitidine, use an oral syringe to measure each dose of the liquid, as it gives a more accurate measurement than household teaspoons. Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications.
If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor. It is important to take this medication exactly as prescribed by your doctor. If you miss a dose, take it as soon as possible and continue with your regular schedule.
If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Store the tablets at room temperature, protect them from light and moisture, and keep them out of the reach of children. Protect it from light, and do not allow it to freeze. Keep it out of the reach of children. Do not dispose of medications in wastewater e. Ask your pharmacist how to dispose of medications that are no longer needed or have expired. Many medications can cause side effects.
0コメント